Clinical Research

Committed to Advancing Patient Care Through Quality Medical Research

Clinical Trials

Participation in ophthalmic research and innovation are an integral part of clinical practice at Vold Vision. We feel strongly that research and innovation enhance patient care, and allow us to give back to our patients and society. With nearly 20 years of clinical research experience, we have found that our patients have benefited tremendously from our clinical research programs. We are extremely excited about some of the break-through technologies we will be able to provide you in the months and years ahead.


Vold Vision is conducting the investigational Light Adjustable Lens (LAL ® )  study and is seeking patients diagnosed with cataracts to participate. 

Introducing the Light Adjustable Lens 

Intraocular lenses (IOLs) have been used in cataract surgery for more than 60 years.  There are many types of replacement lenses available, but one of the critical drawbacks to even modern lens design is the difficulty of achieving optimal visual outcomes. Despite careful measurements of the eye prior to surgery, several factors including preexisting corneal astigmatism and unpredictable wound healing can result in suboptimal patient vision after lens implantation. This can require the patient to wear glasses or have subsequent surgery, such as LASIK, in order to achieve their best visual acuity.

The investigational Light Adjustable Lens is designed to allow your surgeon to adjust the power of the lens. This capability will potentially allow a level of customization and precision, and the ability to correct astigmatism without additional surgery.

Qualified participants will be compensated for full participation in the study.

In order to qualify, patients must:

–        Be between the ages of 40 and 80

–        Have high astigmatism (between 0.75 and 2.00 diopters)

–        Have a cataract

–        Have NOT had previous eye surgery

–        Meet additional inclusion criteria

Please call or email Scott Hewitt for more information on the Light Adjustable Lens clinical study:

479-442-8653 (Vold) or shewitt@voldvision.com

Caution: The LAL is an investigational device and is limited by United States federal law to investigational use only.


Current Clinical Trials

1. A Prospective, Randomized, Comparative, Multicenter Clinical Study To Assess The Safety and Effectiveness of the Transcend CyPass Glaucoma Implant in Patients with Open Angle Glaucoma Undergoing Cataract Surgery (FDA Phase II/III Study Protocol TMI-09-01)

  • Sponsor: Transcend Medical, Inc.
  • Principal Investigator (first study site in United States)

2. A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Implant in Subjects with Refractory Glaucoma (FDA Phase II/III Study  Protocol #REF-001)

  • Sponsor: AqueSys, Inc.
  • Principal Investigator

3. Comparative Study of the Safety and Effectiveness of Ologen Collagen Matrix versus Mitomycin-C in Glaucoma Filtering Surgery

  • Sponsor: Aeon Astron Europe B.V.
  • Principal Investigator

4. A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G#3 in Conjunction with Cataract Surgery (Protocol GC-007)

  • Sponsor:  Glaukos
  • Principal Investigator

5. A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 using the G2-M-IS Injector System in Conjunction with Cataract Surgery (Protocol GC-008)

  • Sponsor:  Glaukos
  • Principal Investigator

6. The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial.  (Protocol  CP 11-001)

  • Sponsor:  Ivantis
  • Principal Investigator

7. Post Approval Study of the AcrySof IQ Toric High Cylinder Power IOL Models SN6AT2 SN6AT9 (Protocol C-11-020)

  • Sponsor:  Alcon
  • Principal Investigator

Past Clinical Trials

1. A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 in Conjunction with Cataract Surgery (FDA Phase II/III Study Protocol #GC-006)

  • Sponsor: Glaukos Corporation
  • Principal Investigator

2. A Randomized, Masked, Phase 2 Study Evaluating Safety and Efficacy of the Latanoprost Punctal Plug Delivery System (L-PPDS) and Comparing with that of Prostaglandin Eye Drops in Subjects with Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)(Protocol PPL GLAU 11)

  • Sponsor: QLT, Inc.
  • Principal Investigator

3. Clinical Evaluation of the TrueVision 3D Visualization and Guidance System for Microsurgery: Toric Intraocular Lens Alignment Template (Protocol 2010-001)

  • Sponsor: TrueVision Systems, Inc.
  • Principal Investigator

4. Clinical Evaluation of the SOLX Gold Shunt for the Reduction of Intraocular Pressure (IOP) in Refractory Glaucoma (Protocol SLX 84)

  • Sponsor: SOLX, Inc.
  • Principal Investigator

5. A Single-Site Pilot Study to Assess the Comfort and Retention of the ForSight Fornix Insert Device in Healthy Volunteers (Protocol #101)

  • Sponsor: ForSight Vision5
  • Principal Investigator

6. Clinical Investigation of AcrySoft IQ Monofocal Toric Intraocular Lens Model SN6AT2 (Protocol C-09-076)

  • Sponosr:  Alcon
  • Principal Investigator